Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 26 to 50 of 2013

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Adalimumab for treating moderate to severe plaque psoriasisTA146
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis BTA96
Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan IHTG467
Adrenal insufficiency: identification and managementNG243
Advanced breast cancer: diagnosis and treatmentCG81
Advocacy services for adults with health and social care needsNG227
Afamelanotide for treating erythropoietic protoporphyriaHST27
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Aflibercept for treating choroidal neovascularisationTA486
Aflibercept for treating diabetic macular oedemaTA346
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Aflibercept solution for injection for treating wet age‑related macular degenerationTA294
Age-related macular degenerationNG82
Agomelatine for the treatment of major depressive episodes (terminated appraisal)TA231
Air pollution: outdoor air quality and healthNG70
Alcohol interventions in secondary and further educationNG135

Results per page

  1. 10
  2. 25
  3. 50
  4. All